Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Janux Therapeutics Inc

Healthcare US JANX

13.76USD
0.17(1.25%)

Last update at 2026-06-04T20:00:00Z

Day Range

13.7114.07
LowHigh

52 Week Range

5.6565.60
LowHigh

Fundamentals

  • Previous Close 13.59
  • Market Cap2352.47M
  • Volume620869
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-70.82500M
  • Revenue TTM7.29M
  • Revenue Per Share TTM0.16
  • Gross Profit TTM -44.82900M
  • Diluted EPS TTM-1.2

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -63.05900M -32.67200M -6.78400M -4.00400M
Minority interest - - - -
Net income -54.15400M -32.55900M -5.25500M -4.23700M
Selling general administrative 22.26M 10.33M 1.80M 0.77M
Selling and marketing expenses - - - -
Gross profit 8.61M 3.64M - -
Reconciled depreciation 0.84M 0.11M 0.01M 0.00600M
Ebit -67.93200M -33.04200M -4.84300M -3.77100M
Ebitda -67.09100M -32.92900M -6.56500M -3.76500M
Depreciation and amortization 0.84M 0.11M -1.72200M 0.00600M
Non operating income net other 4.03M 0.26M - -
Operating income -67.09100M -32.92900M -4.84300M -3.77100M
Other operating expenses 75.70M 36.57M 4.84M 3.77M
Interest expense 4.03M 0.37M 0.21M 0.23M
Tax provision - - - -
Interest income 4.03M 0.26M - -
Net interest income 4.03M 0.26M -0.20600M -0.23300M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -8.90500M -0.11300M -1.52900M 0.23M
Total revenue 8.61M 3.64M 0.00000M 0.00000M
Total operating expenses 75.70M 36.57M 4.84M 3.77M
Cost of revenue 75.70M 36.57M - -
Total other income expense net 4.03M 0.26M -1.94100M -0.23300M
Discontinued operations - - - -
Net income from continuing ops -63.05900M -32.67200M -6.78400M -4.00400M
Net income applicable to common shares -63.05900M -32.67200M -6.78400M -4.00400M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 380.41M 364.01M 379.82M 16.22M 0.68M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.21M 5.42M 2.05M 0.25M -
Total liab 36.06M 43.27M 13.50M 30.86M 8.62M
Total stockholder equity 344.35M 320.74M 366.33M -14.63800M -7.94400M
Deferred long term liab - - - - -
Other current liab 7.39M 8.18M 4.98M 0.05M 0.36M
Common stock 0.05M 0.04M 0.04M 0.00100M 0.00100M
Capital stock 0.05M 0.04M 0.04M 0.00100M 0.00100M
Retained earnings -168.76300M -110.47000M -47.41100M -14.73900M -7.95500M
Other liab - 2.22M 0.70M 6.05M -
Good will - - - - -
Other assets - 2.21M 1.21M - -
Cash 19.20M 51.43M 35.58M 7.81M 0.66M
Cash and equivalents - - - - -
Total current liabilities 13.03M 16.51M 12.80M 3.18M 4.63M
Current deferred revenue 1.71M 5.41M 5.16M 1.95M -
Net debt 5.34M -26.12100M -35.38800M -7.81300M 3.34M
Short term debt 1.52M 0.76M 0.19M 0.75M 4.00M
Short long term debt - - - - 4.00M
Short long term debt total 24.54M 25.30M 0.19M - 4.00M
Other stockholder equity 512.40M 432.70M 34.14M 0.10M 0.01000M
Property plant equipment - 7.09M 1.60M 0.15M 0.02M
Total current assets 349.24M 332.44M 377.02M 16.06M 0.66M
Long term investments - - - - -
Net tangible assets - 320.74M 366.33M -14.63800M -7.94400M
Short term investments 324.82M 275.59M 339.38M - -
Net receivables 2.20M 0.70M 0.20M 8.00M 0.00000M
Long term debt - - - - -
Inventory -2.20000M - - - -
Accounts payable 2.42M 2.16M 2.46M 0.43M 0.27M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.67M -1.53500M -0.27000M - -
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -110.47000M -47.41100M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.33M 2.21M 1.21M - -
Deferred long term asset charges - - - - -
Non current assets total 31.17M 31.57M 2.81M 0.15M 0.02M
Capital lease obligations 24.54M 25.30M 0.19M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 64.71M -339.48100M -339.48100M -339.48100M
Change to liabilities 5.63M 0.00200M 8.01M 0.00400M
Total cashflows from investing activities 58.27M -340.96300M -340.96300M -340.96300M
Net borrowings 23.42M 180.55M 2.50M 4.00M
Total cash from financing activities 0.50M 386.52M 11.52M 4.00M
Change to operating activities 2.81M 0.84M 0.38M -0.07300M
Net income -63.05900M -32.67200M -6.78400M -4.00400M
Change in cash 15.84M 28.59M 7.16M 0.17M
Begin period cash flow 36.40M 7.81M 0.66M 0.49M
End period cash flow 52.24M 36.40M 7.81M 0.66M
Total cash from operating activities -42.92200M -16.97600M -4.36900M -3.82800M
Issuance of capital stock 0.00000M 384.71M 8.95M 0.00000M
Depreciation 0.84M 0.11M 0.01M 0.00600M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - 0.83M 0.38M -
Change to account receivables 0.00000M 8.00M -8.00000M -8.00000M
Sale purchase of stock - 204.17M - -
Other cashflows from financing activities 58.27M 182.36M 11.52M 4.00M
Change to netincome 17.20M 6.74M 2.01M 0.24M
Capital expenditures 6.45M 1.48M 1.48M 1.48M
Change receivables - 8.00M - -
Cash flows other operating -1.35000M -2.18800M - -
Exchange rate changes - - - -
Cash and cash equivalents changes 15.84M 28.59M - -
Change in working capital 4.28M 8.84M 0.39M -0.06900M
Stock based compensation 17.20M 6.91M 0.07M 0.00600M
Other non cash items -2.18300M -0.16900M 1.94M 0.23M
Free cash flow -49.36700M -18.45800M -4.36900M -3.82800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
JANX
Janux Therapeutics Inc		 0.17 1.25% 13.76 - - 336.50 7.90 296.97 -33.7973
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics Inc

10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. David Alan Campbell Ph.D. Pres, CEO & Director 1960
Dr. Wayne Godfrey M.D. Chief Medical Officer 1961
Mr. Tighe M. Reardon C.F.A., CPA, CPA Acting Chief Financial Officer 1976
Mr. Tommy Diraimondo Ph.D. Sr. Director of Research NA
Ms. Brenda Van Vreeswyk Head of HR NA
Mr. Andy Hollman Meyer Chief Bus. Officer 1984
Mr. Charles M. Winter Sr. VP of Chemistry, Manufacturing & Controls NA
Mr. Byron Robinson J.D., Ph.D. Chief Strategy Officer 1965
Dr. David Alan Campbell Ph.D. President, CEO & Director 1960
Mr. Tighe M. Reardon C.F.A., CPA Acting Chief Financial Officer 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.